The BPC-157 / TB-500 Blend is a defined two-component research reference material combining a gastric-derived pentadecapeptide reference with a thymosin-beta-4 fragment reference. Because it is a blend, it has no single molecular identity, CAS number, or molecular weight; each component must be characterized separately.
Why a blend needs careful labeling
A two-component material is not one new molecule. The analytical identity of BPC-157 and TB-500 remains separate, as do their purity measurements, molecular masses, degradation profiles, and literature histories. A useful COA should identify both components and the total blend strength without implying that a single number describes both substances.
Component research contexts
BPC-157 is studied as a synthetic pentadecapeptide in cytoprotection, nitric-oxide, endothelial, and growth-factor-related model systems. TB-500 is commonly described as an N-acetylated thymosin-beta-4 fragment used in actin-binding and cytoskeletal research. These are distinct research questions. Combining the components in one sample does not prove synergy or a shared mechanism.
Experimental controls
Blend experiments should include component-specific analytical controls, a formulation or vehicle control, and—when the question requires it—single-component comparators. Researchers should document the proportion of each component, the assay’s ability to distinguish them, and whether an observed signal could arise from degradation products or matrix effects. Results should be reported as blend experiments, not as evidence for an untested combined clinical effect.
Research-only terms
Use lot-specific documentation, SDS guidance, institutional procedures, and appropriate contamination and waste controls. The blend is supplied as a laboratory reference material only. It is not for human or veterinary use, diagnosis, or treatment, and this page does not provide reconstitution, dosing, or administration instructions.
Every BPC-157 / TB-500 Blend order includes a sealed, lot-controlled vial, the completed lot documentation, and a handling & storage card. Product-specific handling follows the supplied documentation and institutional SOPs.
Evidence limits and research safety
Research findings can differ by model, assay, purity, formulation, and study design. Published cell, biochemical, and pre-clinical observations do not establish human or veterinary safety, efficacy, dosing, or suitability. Researchers should review the applicable SDS, institutional safety procedures, waste requirements, and lot-specific documentation before handling any reference material.
Related research
KLOW Blend · BPC-157 · TB-500
Credible sources
- PubChem — BPC-157 search
- PubChem — thymosin beta-4 / TB-500 search
- PubMed — BPC-157 and TB-500 research literature